Blau Farmacêutica S.A. (BLAU3.SA)

Blau Farmacêutica S.A. (BLAU3.SA) — VMCI valuation read

Across 120 indicators, Blau Farmacêutica S.A. (BLAU3.SA) lands at VMCI 52/100. The Healthcare sector median is 50, so the 2-point above-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on BLAU3.SA in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, BLAU3.SA trades at 23.0x earnings, 28% above the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 9.0% trails the Healthcare median (10.0%) by 1.0pp. On Risk, net debt to EBITDA of 0.2x leaves covenant headroom for BLAU3.SA on the trailing balance sheet.

BLAU3.SA fell 2.6% over the trailing 7 days, with a +7.8% read on a 30-day basis.